Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Phase 2 Completed 182 enrolled Medical University of South Carolina National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized controlled Phase II clinical trial designed to evaluate the effects of N-acetylcysteine (NAC) in reducing Alcohol Use Disorder (AUD) severity and Post Traumatic Stress Disorder (PTSD) symptomatology among individuals with current AUD and PTSD.

Timeline

Start: 2016-10-01
Primary completion: 2021-09-16
Completion: 2022-09-19

Publications

Back SE, Gray K, Jarnecke AM, Saraiya TC, Santa Ana EJ, Killeen T, Joseph JE, Prisciandaro JJ, Brown DG, Nietert PJ, Stecker T, Rothbaum A, Jones JL, Flanagan JC, Brady KT. N-Acetylcysteine for the Treatment of Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial. J Clin Psychiatry. 2025 Aug 27;86(4):25m15803. doi: 10.4088/JCP.25m15803.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N-acetylcysteine	Small molecule	2400 mg	—

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Summary

Timeline

Publications

Drugs

Indications